Asset profile

tirzepatide · Zepbound / Mounjaro

Peptide

Approvedregulatory verdict

Evidence outlook

Approved — Type 2 Diabetes, Obesity

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Atherosclerotic Cardiovascular Disease

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(40 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (7)

August 2026 (2)

Phase 2ObesityActive not recruiting

Est. primary completion 2026-08-22 · NCT06965413 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2ObesityRecruiting

Est. primary completion 2026-08-31 · NCT06994338 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2026 (1)

Phase 2Type 2 DiabetesActive not recruiting

Est. primary completion 2026-09 · NCT05536804 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (2)

Phase 3ObesityActive not recruiting

Est. primary completion 2026-11 · NCT06962280 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3ObesityActive not recruiting

Est. primary completion 2026-11 · NCT06914895 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (2)

Phase 3ObesityNot yet recruiting

Est. primary completion 2026-12 · NCT07298915 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2ObesityRecruiting

Est. primary completion 2026-12-31 · NCT06802081 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (17)

January 2027 (1)

Phase 2/3ObesityActive not recruiting

Est. primary completion 2027-01-01 · NCT06162715 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (2)

Phase 3Type 2 DiabetesRecruiting

Est. primary completion 2027-02-14 · NCT07481747 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2ObesityRecruiting

Est. primary completion 2027-02-15 · NCT07245771 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (2)

Phase 2ObesityRecruiting

Est. primary completion 2027-04-01 · NCT06811324 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2ObesityRecruiting

Est. primary completion 2027-04-27 · NCT07463846 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (1)

Phase 2ObesityNot yet recruiting

Est. primary completion 2027-05-15 · NCT07292519 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (1)

Phase 3ObesityNot yet recruiting

Est. primary completion 2027-06-11 · NCT07738276 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (1)

Phase 2ObesityNot yet recruiting

Est. primary completion 2027-07 · NCT07671391 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (1)

Phase 2ObesityNot yet recruiting

Est. primary completion 2027-08-15 · NCT06732245 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (3)

Phase 2ObesityRecruiting

Est. primary completion 2027-09 · NCT06143956 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2ObesityRecruiting

Est. primary completion 2027-09-17 · NCT06700538 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast CancerRecruiting

Est. primary completion 2027-09-30 · NCT06518837 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (2)

Phase 3ObesityActive not recruiting

Est. primary completion 2027-10 · NCT05556512 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3ObesityRecruiting

Est. primary completion 2027-10 · NCT06439277 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)

Phase 2ObesityRecruiting

Est. primary completion 2027-11 · NCT07228741 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (2)

Phase 2ObesityRecruiting

Est. primary completion 2027-12-01 · NCT06847399 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Type 1 Diabetes MellitusRecruiting

Est. primary completion 2027-12-31 · NCT06820281 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (11)

January 2028 (1)

Phase 2/3Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes MellitusRecruiting

Est. primary completion 2028-01 · NCT07284511 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (1)

Phase 2Hormone-receptor-positive Breast Cancer, Early Breast CancerNot yet recruiting

Est. primary completion 2028-03-01 · NCT07676331 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2028 (1)

Phase 3ObesityRecruiting

Est. primary completion 2028-04 · NCT06937086 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (2)

Phase 2Crohn Disease (CD)Recruiting

Est. primary completion 2028-05 · NCT06976853 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3ObesityRecruiting

Est. primary completion 2028-05 · NCT06937099 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (1)

Phase 2ObesityRecruiting

Est. primary completion 2028-06 · NCT05912621 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (2)

Phase 2Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism, Schizophrenia Disorders …Recruiting

Est. primary completion 2028-08-01 · NCT06939088 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2ObesityNot yet recruiting

Est. primary completion 2028-08-15 · NCT07747805 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (3)

Phase 2ObesityNot yet recruiting

Est. primary completion 2028-12 · NCT06180616 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2ObesityRecruiting

Est. primary completion 2028-12-31 · NCT05933499 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaNot yet recruiting

Est. primary completion 2028-12-31 · NCT07349641 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (4)

March 2029 (1)

Phase 2Endometrial Cancer, Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid CarcinomaNot yet recruiting

Est. primary completion 2029-03 · NCT07078838 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2029 (1)

Phase 3Type 2 DiabetesRecruiting

Est. primary completion 2029-04-30 · NCT06246799 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2029 (1)

Phase 2ObesityRecruiting

Est. primary completion 2029-06-30 · NCT06582875 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2029 (1)

Phase 2Breast Cancer, Breast Neoplasms, Breast CancersRecruiting

Est. primary completion 2029-08-31 · NCT06517212 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (1)

February 2030 (1)

Phase 2ObesityNot yet recruiting

Est. primary completion 2030-02-01 · NCT07693608 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.